西證國際證券(0812.HK):接獲上市複核委員會函件 繼續停牌
格隆匯3月19日丨西證國際證券(0812.HK)發佈公吿,上市複核委員會對上市委員會決定的復核聆訊(“上市復核委員會聆訊”)已於2024年3月5日舉行。2024年3月18日,公司接獲上市復核委員會函件,通知上市復核委員會在考慮公司及上市科提交的所有書面及口頭呈件後,認為公司未能維持上市規則第13.24條所規定的足夠營運及資產水平,以保證公司股份繼續上市,並決定維持根據上市規則第6.01(3)條暫停股份買賣的上市委員會決定(“上市復核委員會決定”)。
公司股份自2024年3月4日上午九時正起於聯交所暫停買賣,並將繼續停牌直至另行通知。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.